Central - Tenders Closing for a specific Date

Report For Day : 13-May-2026

Total Tenders : 1955
Sl.No e-Published Date Bid Submission Closing Date Tender Opening Date Title/Ref.No./Tender Id State Name Corrigendum
281. 10-Apr-2026 07:45 PM 13-May-2026 10:45 AM 13-May-2026 10:45 AM CHROMEPLATED MS FLEXIBLE COOLENT PIPE/P1261756/107021757 Ministry of Railways --
282. 22-Apr-2026 05:24 PM 13-May-2026 10:45 AM 13-May-2026 10:45 AM HERPES ZOSTER VACCINE RECOMBINANT, ADJUVANTED 50 MCG SINGLE DOSE 0.5 ML VIAL/P2265346/107032697 Ministry of Railways --
283. 04-May-2026 05:34 PM 13-May-2026 10:45 AM 13-May-2026 10:45 AM BUDESONIDE 200 MCG AND FORMOTEROL FUMARA [BUDESONIDE 200 MCG AND FORMOTEROL FUMARATE 6 MCG INHALER]/P6265501/107043845 Ministry of Railways --
284. 22-Apr-2026 05:28 PM 13-May-2026 10:45 AM 13-May-2026 10:45 AM DARBEPOETIN ALFA 40 MCG PER 0.4 ML PFS INJECTION (QUANTITY 100 NUMBERS IMMEDIATE SUPPLY REMAINING AS PER CONSIGNEE REQUEST)/P2265350/107032677 Ministry of Railways --
285. 06-May-2026 11:02 AM 13-May-2026 10:45 AM 13-May-2026 10:45 AM CLUTCH PLATE/P6265390C/107045597 Ministry of Railways --
286. 22-Apr-2026 05:27 PM 13-May-2026 10:45 AM 13-May-2026 10:45 AM INSULIN RECOMBINANT DNA ORIGIN 50 Percent INSULIN LISPRO AND 50 Percent INSULIN LISPRO PROTAMINE SUSPENSION - 100 IU X 1 ML X 3 ML- PENFILLS/ CARTRIDGES INJECTION/P2265343/107032682 Ministry of Railways --
287. 22-Apr-2026 05:25 PM 13-May-2026 10:45 AM 13-May-2026 10:45 AM GABAPENTIN 300 MG AND METHYLCOBALAMIN 500 MCG ORAL TABLET/P2265354/107032683 Ministry of Railways --
288. 22-Apr-2026 05:22 PM 13-May-2026 10:45 AM 13-May-2026 10:45 AM METOPROLOL XL 50 MG ORAL TABLET/P2265324/107032702 Ministry of Railways --
289. 22-Apr-2026 12:45 PM 13-May-2026 10:55 AM 13-May-2026 10:55 AM HOOK DRG.NO. as per Drg. No. 3 10113.0.09.095.012, ALT- A ./30262217B/107032177 Ministry of Railways --
290. 02-May-2026 04:09 PM 13-May-2026 10:55 AM 13-May-2026 10:55 AM CORONA RESISTANT ROUND ENAMELED/40263151/107042695 Ministry of Railways --

Note : For more details and clarifications, please refer to the respective Portal.